AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05392127
Drug: Warfarin Sodium Tablets
RxNorm normalized name: Warfarin Sodium Tablets
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin Sodium Tablets single dose
Trial: NCT05392127
Drug: Omeprazole Enteric Capsules
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole Enteric Capsules single dose
Trial: NCT05392127
Drug: Vitamin K1 Tablets
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 Tablets once daily
Trial: NCT05392127
Drug: Repaglinide Tablets
RxNorm normalized name: Repaglinide Tablets
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide Tablets single dose
Trial: NCT05238948
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Substrate of CYP3A4
Trial: NCT05238948
Drug: CKD-506
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perpetrator of CYP3A4
Trial: NCT04684550
Drug: Stabilized hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
Trial: NCT04446793
Drug: Onvansertib
RxNorm normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
Trial: NCT05076851
Drug: Proxalutamide
RxNorm normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
Trial: NCT05699746
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
Trial: NCT01134692
Drug: Propranolol, Norfloxacin, VSL#3
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol: as per heart rate titration Norfloxacin: 400mg BD
Trial: NCT05804305
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol is a prostaglandin E1 analogue
Trial: NCT05920512
Drug: Sodium valproate extended-release tablets
RxNorm normalized name: valproate Extended Release Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
Trial: NCT00000748
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04808154
Drug: SNP-630
RxNorm normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
Trial: NCT06357806
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/10ml/1bottle
Trial: NCT06357806
Drug: Peg-IFNα-2b
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180ug/0.5ml/1bottle
Trial: NCT05218850
Drug: Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butyrate enemas will be administered once a day for 12 weeks
Trial: NCT05279833
Drug: dronedarone
RxNorm normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form is tablet and route of administration is oral
Trial: NCT05279833
Drug: sotalol
RxNorm normalized name: Sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form is tablet and route of administration is oral
Trial: NCT05404945
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 400 mg IV
Trial: NCT05404945
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine 6mg/m2 IV
Trial: NCT05404945
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine 375mg/m2 IV
Trial: NCT05404945
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1.8 mg/kg IV
Trial: NCT05508776
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet
Trial: NCT04749979
Drug: HCG ( eg. Choriomon )
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: giving HCG
Trial: NCT05332067
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe
Trial: NCT05599126
Drug: Mianserin
RxNorm normalized name: mianserin
DrugBank: Mianserin (DB06148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
Trial: NCT05599126
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
Trial: NCT05913427
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).
Trial: NCT05623904
Drug: Medical Treatment
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.
Trial: NCT06474273
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Methylprednisolone
Trial: NCT06474273
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone augmentation
Trial: NCT06103695
Drug: Tapinarof
RxNorm normalized name: Tapinarof
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add on Vtama (tapinarof) to biololgic therapy
Trial: NCT06553339
Drug: Oral HS-10516
RxNorm normalized name: estrogens, esterified (USP)
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIF-2α inhibitor
Trial: NCT05053087
Drug: Ropivacaine Continuous Infusion
RxNorm normalized name: Uniphyllin Continus
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% continuous infusion 6mL/hr
Trial: NCT04030052
Drug: Nuwiq (low dose protocol)
RxNorm normalized name: Nuwiq
DrugBank: Simoctocog alfa (DB09108)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
Trial: NCT04030052
Drug: HEMLIBRA
RxNorm normalized name: Hemlibra
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
Trial: NCT05053087
Drug: Ropivacaine Intermittent Bolus
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% intermittent bolus infusion 8mL every 2 hours
Trial: NCT04885829
Drug: Tocilizumab Prefilled Syringe
RxNorm normalized name: tocilizumab Prefilled Syringe
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
Trial: NCT04030052
Drug: Nuwiq (Atlanta protocol)
RxNorm normalized name: Nuwiq
DrugBank: Simoctocog alfa (DB09108)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
Trial: NCT05480787
Drug: Remimazolam 0.1mg/kg/h
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam Tosilate for Injection(36mg)
Trial: NCT05480787
Drug: Remimazolam 0.3mg/kg/h
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam Tosilate for Injection(36mg)
Trial: NCT05480787
Drug: Remimazolam 0.5mg/kg/h
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam Tosilate for Injection(36mg)
Trial: NCT03306615
Drug: Hyaluronidase
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
Trial: NCT06376916
Drug: Magnesium Sulfate 2 G
RxNorm normalized name: magnesium sulfate 2 GM in 50 ML Injection
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Trial: NCT06376916
Drug: Magnesium Sulfate 4 G
RxNorm normalized name: magnesium sulfate 4 GM in 50 ML Injection
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Trial: NCT06376916
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Trial: NCT06101394
Drug: Cetuximab-IRDye800
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
Trial: NCT04786873
Drug: Macimorelin
RxNorm normalized name: Macimorelin
DrugBank: Macimorelin (DB13074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
Trial: NCT04718181
Drug: risdiplam
RxNorm normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
Trial: NCT04718181
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
Trial: NCT04693897
Drug: Mirabegron 50 MG
RxNorm normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
Trial: NCT04693897
Drug: Solifenacin Succinate 5 MG
RxNorm normalized name: solifenacin succinate 5 MG
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
Trial: NCT00000741
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04735367
Drug: palbociclib plus letrozole
RxNorm normalized name: Palbociclib
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palbociclib plus letrozole
Trial: NCT05014594
Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy
RxNorm normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
Trial: NCT06308939
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.4mg/m\^2 day1、8，repeated every 3 week.
Trial: NCT06308939
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg once every three weeks.
Trial: NCT05418244
Drug: Oral Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg oral disintegrating ondansetron tablet once
Trial: NCT00002058
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04398719
Drug: Low-dose lipopolysaccharide
RxNorm normalized name: ethinyl estradiol
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravenous lipopolysaccharide.
Trial: NCT04398719
Drug: Intradermal Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A small dose of capsaicin will be administered by intradermal injection.
Trial: NCT06520176
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1\~Day 2: 75mg/m\^2
Trial: NCT06520176
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1\~Day 2: 200g/m\^2, q12h
Trial: NCT06520176
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Day 6: 6mg
Trial: NCT06520176
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
Trial: NCT06520176
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Trial: NCT05118386
Drug: RSM01
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM
Trial: NCT00006630
Drug: Vaccinia Immune Globulin (Human)
RxNorm normalized name: Vaccinia Immune Globulin (Human) Intravenous
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04671914
Drug: Hyaluronic Acid 20 MG/ML Injectable Solution
RxNorm normalized name: hyaluronic acid 20 MG/ML Injectable Solution
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
Trial: NCT06434103
Drug: SHR-A1921；Adebrelimab；SHR-8068；carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
Trial: NCT05087602
Drug: Toripalimab and Anlotinib
RxNorm normalized name: Toripalimab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Trial: NCT00000728
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000728
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04657016
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05249231
Drug: Silver diamine fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
Trial: NCT05161351
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
Trial: NCT05161351
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be vitamin D3, (colecalciferol).
Trial: NCT05582811
Drug: Dose Riociguat 2,5 or 5mg
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Trial: NCT05582811
Drug: Riociguat
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Trial: NCT05201859
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
Trial: NCT06548945
Drug: GZR18
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg-maximum tolerated dose (MTD), single dose
Trial: NCT06324994
Drug: Linperlisib in combination with Obinutuzumab and Venetoclax
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.